Vertex Pharmaceuticals Incorporated (BMV:VRTX)

Market Cap	2.21T
Revenue (ttm)	226.87B
Net Income (ttm)	-20.21B
Shares Out	n/a
EPS (ttm)	-78.52
PE Ratio	n/a
Forward PE	23.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51
Average Volume	660
Open	8,630.45
Previous Close	n/a
Day's Range	8,630.45 - 8,784.00
52-Week Range	7,488.30 - 10,477.52
Beta	0.51
RSI	45.22
Earnings Date	Aug 4, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: VRTX

Financial Performance

Financial numbers in USD